#Imugene = Too much emphasis on #patents instead of products; in this case, #patent #monopolies from #EPO whose own examiners complain about invalid grants https://www.proactiveinvestors.com/companies/news/972724/imugene-welcomes-new-chief-medical-officer-and-talks-significant-new-patents-972724.html http://techrights.org/2021/12/28/epo-wont-invest-in-staff-and-in-quality/
There are no comments yet.